Functional role of inorganic trace elements in angiogenesis-Part I: N, Fe, Se, P, Au, and Ca

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 129-142

  Saghiri, Mohammad Ali ^a   Asatourian, Armen ^b   Orangi, Jafar ^b   Sorenson, Christine M ^a   Sheibani, Nader ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Kamal Asgar Research Center   (Iran)

Author keywords

Angiogenesis; Endothelial cells; Inorganic elements; Wound healing

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEFEROXAMINE; DIMETHYL SELENIDE; GOLD; GOLD NANOPARTICLE; IRON; METHYLSELENOCYSTEINE; METHYLSELENOL; NICKEL; NITRIC OXIDE; PAMIDRONIC ACID; PHOSPHORUS; SELENIUM; SELENIUM DERIVATIVE; SELENODIGLUTATHIONE; SELENOMETHIONINE; SELENOTRISULFIDE; SODIUM SELENITE; TRIMETHYLSELENONIUM; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANGIOGENESIS INHIBITOR; NITROGEN; TRACE ELEMENT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CALCIUM SIGNALING; CANCER INHIBITION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; IRON CHELATION; IRON DEFICIENCY; NONHUMAN; OVARY CANCER; REVIEW; SYSTEMATIC REVIEW; ANIMAL; DRUG EFFECTS; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; CALCIUM; GOLD; HUMANS; IRON; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITROGEN; PHOSPHORUS; SELENIUM; TRACE ELEMENTS;

EID: 84942192584     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.010     Document Type: Review

References (147)

1. Briggs D. Environmental pollution and the global burden of disease. Br Med Bull 2003, 68:1-24.
2. Anand P., Kunnumakara A.B., Sundaram C., et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008, 25:2097-2116.
3. Plum L.M., Rink L., Haase H. The essential toxin: impact of zinc on human health. Int J Env Res Public Health 2010, 7:1342-1365.
4. Monteilh-Zoller M.K., Hermosura M.C., Nadler M.J., Scharenberg A.M., Penner R., Fleig A. TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. J Gen Physiol 2003, 121:49-60.
5. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
6. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
7. McDonald D.M., Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003, 9:713-725.
8. Lyden D., Hattori K., Dias S., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201.
9. Folkman J., Kalluri R. Cancer without disease. Nature 2004, 427:787.
10. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
11. Featherstone J., Griffiths S. Drugs that target angiogenesis. Nat Rev Drug Discov 2002, 1:413-414.
12. Risau W., Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995, 11:73-91.
13. Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 2000, 50:1-15.
14. Flamme I., Frölich T., Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 1997, 173:206-210.
15. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-396.
16. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
17. Semenza G.L. Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem 2007, 102:840-847.
18. Stresing V., Fournier P.G., Bellahcène A., et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 2011, 48:259-266.
19. Mönkkönen H., Kuokkanen J., Holen I., et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anti-Cancer Drugs 2008, 19:391-399.
20. Roelofs A.J., Jauhiainen M., Mönkkönen H., Rogers M.J., Mönkkönen J., Thompson K. Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009, 144:245-250.
21. Räikkönen J., Crockett J.C., Rogers M.J., Mönkkönen H., Auriola S., Mönkkönen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009, 157:427-435.
22. Stresing V., Daubiné F., Benzaid I., Mönkkönen H., Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007, 257:16-35.
23. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
24. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
25. Ribatti D., Nico B., Mangieri D., et al. Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol 2007, 26:1094-1098.
26. Hasmim M., Bieler G., Rüegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 2007, 5:166-173.
27. Santini D., Vincenzi B., Avvisati G., et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002, 8:1080-1084.
28. Melani C., Sangaletti S., Barazzetta F.M., Werb Z., Colombo M.P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67:11438-11446.
29. Matsunaga T., Weihrauch D.W., Moniz M.C., Tessmer J., Warltier D.C., Chilian W.M. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 2002, 105:2185-2191.
30. Chen C-H., Cartwright J., Li Z., et al. Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants Essential role of basic fibroblast growth factor. Atertio Thromb Vasc Biol 1997, 17:1303-1312.
31. Van Belle E., Rivard A., Chen D., et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997, 96:2667-2674.
32. Murohara T., Witzenbichler B., Spyridopoulos I., et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Atertio Thromb Vasc Biol 1999, 19:1156-1161.
33. Rössig L., Fichtlscherer B., Breitschopf K., et al. Nitric oxide inhibits caspase-3 by S-nitrosationin vivo. J Biol Chem 1999, 274:6823-6826.
34. Ziche M., Morbidelli L., Choudhuri R., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997, 99:2625-2634.
35. Hudlicka O. Is physiological angiogenesis in skeletal muscle regulated by changes in microcirculation. Microcirculation 1998, 5:7-23.
36. Anderson J., Fitzgerald C. Iron: an essential nutrient 2010, Available from 〈http://www.ext.colostate.edu/pubs/foodnut/09356.html〉.
37. Ohara T., Noma K., Urano S., et al. A novel synergistic effect of iron depletion on antiangiogenic cancer therapy. Int J Cancer 2013, 132:2705-2713.
38. Dongiovanni P., Valenti L., Ludovica Fracanzani A., Gatti S., Cairo G., Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008, 172:738-747.
39. Salnikow K., Donald S.P., Bruick R.K., Zhitkovich A., Phang J.M., Kasprzak K.S. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004, 279:40337-40344.
40. 2 availability on human cancer. Nat Rev Cancer 2008, 8:967-975.
41. Le N.T., Richardson D.R. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002, 1603:31-46.
42. Hu G.F. Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem 1998, 69:326-335.
43. Babitt J.L., Lin H.Y. The molecular pathogenesis of hereditary hemochromatosis. Semin Liver Dis 2011, 31:280-292.
44. Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012, 1823:1434-1443.
45. Kaplan J., Ward D.M., De Domenico I. The molecular basis of iron overload disorders and iron-linked anemias. Int J Hematol 2011, 93:14-20.
46. Gnana-Prakasam J.P., Martin P.M., Smith S.B., Ganapathy V. Expression and function of iron-regulatory proteins in retina. IUBMB Life 2010, 62:363-370.
47. Song D., Dunaief J.L. Retinal iron homeostasis in health and disease. Front Aging Neurosci 2013, 5:24.
48. Tawfik A., Gnana-Prakasam J.P., Smith S.B., Ganapathy V. Deletion of hemojuvelin, an iron-regulatory protein, in mice results in abnormal angiogenesis and vasculogenesis in retina along with reactive gliosis. Invest Ophthalmol Visual Sci 2014, 8:3616-3625.
49. Cai J., Pardali E., Sánchez-Duffhues G., ten Dijke P. BMP signaling in vascular diseases. FEBS Lett 2012, 586:1993-2002.
50. Beets K., Huylebroeck D., Moya I.M., Umans L., Zwijsen A. Robustness in angiogenesis: notch and BMP shaping waves. Trends Genet 2013, 29:140-149.
51. Stirnberg M., Gutschow M. Matriptase-2, a regulatory protease of iron homeostasis: possible substrates, cleavage sites and inhibitors. Curr Pharm Des 2013, 19:1052-1061.
52. Eckard J., Dai J., Wu J., et al. Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Cancer Cell Int 2010, 10:28.
53. Wilhelm C., Billotey C., Roger J., Pons J., Bacri J-C., Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003, 24:1001-1011.
54. Metz S., Bonaterra G., Rudelius M., Settles M., Rummeny E.J., Daldrup-Link H.E. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004, 14:1851-1858.
55. Gojova A., Guo B., Kota R.S., Rutledge J.C., Kennedy I.M., Barakat A.I. Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effect of particle composition. Environ Health Perspect 2007, 115:403-409.
56. Müller K., Skepper J.N., Posfai M., et al. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials 2007, 28:1629-1642.
57. Wittenborn T.R., Larsen E.K., Nielsen T., et al. Accumulation of nano-sized particles in a murine model of angiogenesis. Biochem Biophys Res Commun 2014, 443:470-476.
58. Moore A., Marecos E., Bogdanov A., Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model 1. Radiology 2000, 214:568-574.
59. Pisanic T.R., Blackwell J.D., Shubayev V.I., Fiñones R.R., Jin S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 2007, 28:2572-2581.
60. Ge G., Wu H., Xiong F., et al. The cytotoxicity evaluation of magnetic iron oxide nanoparticles on human aortic endothelial cells. Nanoscale Res Lett 2013, 8:1-10.
61. Ho D.N., Kohler N., Sigdel A., et al. Penetration of endothelial cell coated multicellular tumor spheroids by iron oxide nanoparticles. Theranostics 2012, 2:66.
62. Zhou Y., Yan H., Guo M., Zhu J., Xiao Q., Zhang L. Reactive oxygen species in vascular formation and development. Oxid Med Cell Longev 2013, 2013. 10.1155/2013/374963.
63. Myllyharju J. HIF prolyl 4-hydroxylases and their potential as drug targets. Curr Pharm Des 2009, 15:3878-3885.
64. Salnikow K., Kasprzak K.S. Ascorbate depletion: a critical step in nickel carcinogenesis?. Environ Health Perspect 2005, 5:7-84.
65. Kim T-H., Hur E-g Kang S-J., et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res 2011, 71:2260-2275.
66. Grochot-Przeczek A., Kotlinowski J., Kozakowska M., et al. Heme oxygenase-1 is required for angiogenic function of bone marrow-derived progenitor cells: role in therapeutic revascularization. Antioxid Redox Signalg 2014, 20:1677-1692.
67. Dulak J., Deshane J., Jozkowicz A., Agarwal A. Heme, oxygenase-1 and carbon monoxide in vascular pathobiology focus on angiogenesis. Circulation 2008, 117:231-241.
68. Zhang J.C., Claffey K., Sakthivel R., et al. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 2000, 14:2589-2600.
69. Coffman L.G., Parsonage D., D'Agostino R., Torti F.M., Torti S.V. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci USA 2009, 106:570-575.
70. Sapieha P., Sirinyan M., Hamel D., et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med 2008, 14:1067-1076.
71. Gnana-Prakasam J.P., Ananth S., Prasad P.D., et al. Expression and iron-dependent regulation of succinate receptor GPR91 in retinal pigment epithelium. Invest Ophthalmol Visual Sci 2011, 52:3751-3758.
72. Jacobs M., Forst C. Toxicological effects of sodium selenite in sprague-dawley rats. J Toxicol Environ Health 1981, 8:575-585.
73. Combs G., Clark L., Turnbull B. An analysis of cancer prevention by selenium. BioFactors 2001, 14:153-159.
74. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998, 128:1845-1854.
75. Corcoran N.M., Najdovska M., Costello A.J. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 2004, 171:907-910.
76. Burk R.F. Selenium, an antioxidant nutrient. Nutr Clin Care 2002, 5:75-79.
77. El-Bayoumy K. Effects of organoselenium compounds on induction of mouse forestomach tumors by benzo(a)pyrene. Cancer Res 1985, 45:3631-3635.
78. Combs G., Clark L.C., Turnbull B.W. Reduction of cancer mortality and incidence by selenium supplementation. Med Klin 1997, 92:42-45.
79. El-Bayoumy K. The role of selenium in cancer prevention. Practice of oncology 1991, 1-15. JB Lippincott, Philadelphia, PA. 4th ed.
80. Ip C., Lisk D.J. Enrichment of selenium in allium vegetables for cancer prevention. Carcinogenesis 1994, 15:1881-1885.
81. Dipple A., Pigott M., Moschel R.C., Costantino N. Evidence that binding of 7,12-dimethylbenz(a)anthracene to DNA in mouse embryo cell cultures results in extensive substitution of both adenine and guanine residues. Cancer Res 1983, 43:4132-4135.
82. Liu J.Z., Milner J.A. Age, dietary selenium and quantity of 7,12-dimethylbenz(a)anthracene influence the in vivo occurrence of rat mammary DNA adducts. J Nutr 1992, 122:1361-1368.
83. Jiang C., Ganther H., Lu J. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulation. Mol Carcinog 2000, 29:236-250.
84. Jacobs M.M., Shubik P., Feldman R. Influence of selenium on vascularization in the hamster cheek pouch. Cancer Lett 1980, 9:353-357.
85. Jiang C., Jiang W., Ip C., Ganther H., Lu J. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 1999, 26:213-225.
86. Levy A.P., Levy N.S., Wegner S., Goldberg M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995, 270:13333-13340.
87. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997, 94:3633-3638.
88. Forsythe J.A., Jiang B-H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
89. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416.
90. Gallegos A., Berggren M., Gasdaska J.R., Powis G. Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. Cancer Res 1997, 57:4965-4970.
91. Berggren M., Gallegos A., Gasdaska J., Powis G. Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res 1996, 17:3377-3380.
92. Christensen M.J., Pusey N.W. Binding of nuclear proteins to transcription regulatory elements in selenium deficiency. Biochim Biophys Acta 1994, 1225:338-341.
93. Spyrou G., Björnstedt M., Kumar S., Holmgren A.A.P-1 DNA-binding activity is inhibited by selenite and selenodiglutathione. FEBS Lett 1995, 368:59-63.
94. Kim I.Y., Stadtman T.C. Inhibition of NF-(B DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment. Proc Natl Acad Sci USA 1997, 94:12904-12907.
95. Prié D., Torres P.U., Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009, 75:882-889.
96. Takeda E., Yamamoto H., Nashiki K., Sato T., Arai H., Taketani Y. Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 2004, 8:191-200.
97. Beck G.R., Moran E., Knecht N. Inorganic phosphate regulates multiple genes during osteoblast differentiation, including Nrf2. Exp Cell Res 2003, 288:288-300.
98. Chang S-H., Yu K.N., Lee Y-S., et al. Elevated inorganic phosphate stimulates Akt-ERK1/2-Mnk1 signaling in human lung cells. Am J Respir Cell Mol Biol 2006, 35:528-539.
99. Jin H., Chang S-H., Xu C-X., et al. High dietary inorganic phosphate affects lung through altering protein translation, cell cycle, and angiogenesis in developing mice. Toxicol Sci 2007, 100:215-223.
100. Lin Y., McKinnon K.E., Ha S.W., Beck G.R. Inorganic phosphate induces cancer cell mediated angiogenesis dependent on forkhead box protein C2 (FOXC2) regulated osteopontin expression. Mol Carcinog 2014, 10.1002/mc.22153.
101. Camalier C.E., Yi M., Yu L.R., et al. An integrated understanding of the physiological response to elevated extracellular phosphate. J Cell Physiol 2013, 228:1536-1550.
102. Mani S.A., Yang J., Brooks M., et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 2007, 104:10069-10074.
103. Hollier B.G., Tinnirello A.A., Werden S.J., et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 2013, 73:1981-1992.
104. El-Tanani M.K., Campbell F.C., Kurisetty V., Jin D., McCann M., Rudland P.S. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006, 17:463-474.
105. Rittling S., Chambers A. Role of osteopontin in tumour progression. Br J Cancer 2004, 90:1877-1881.
106. Hirama M., Takahashi F., Takahashi K., et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003, 198:107-117.
107. Beck G.R., Knecht N. Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent. J Biol Chem 2003, 278:41921-41929.
108. Xu C-X., Jin H., Lim H-T., et al. Low dietary inorganic phosphate stimulates lung tumorigenesis through altering protein translation and cell cycle in K-ras LA1 mice. Nutr Cancer 2010, 62:525-532.
109. Di Marco G.S., König M., Stock C., et al. High phosphate directly affects endothelial function by downregulating annexin II. Kidney Int 2012, 83:213-222.
110. Di Marco G.S., Hausberg M., Hillebrand U., et al. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol: Ren Physiol 2008, 294:1381-1387.
111. Mansfield K., Teixeira C., Adams C., Shapiro I. Phosphate ions mediate chondrocyte apoptosis through a plasma membrane transporter mechanism. Bone 2001, 28:1-8.
112. Meleti Z., Shapiro I., Adams C. Inorganic phosphate induces apoptosis of osteoblast-like cells in culture. Bone 2000, 27:359-366.
113. Stoneman V.E., Bennett M.R. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci 2004, 107:343-354.
114. Pissuwan D., Valenzuela S.M., Cortie M.B. Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends Biotechnol 2006, 24:62-67.
115. Giljohann D.A., Seferos D.S., Daniel W.L., Massich M.D., Patel P.C., Mirkin C.A. Gold nanoparticles for biology and medicine. Angew Chem Int Ed 2010, 49:3280-3294.
116. Conde J., Doria G., Baptista P. Noble metal nanoparticles applications in cancer. J Drug Deliv 2012, 2012. 10.1155/2012/751075.
117. Bao C., Conde J., Polo E., et al. A promising road with challenges: where are gold nanoparticles in translational research. Nanomedicine 2014, 9:2353-2370.
118. Arvizo R.R., Saha S., Wang E., Robertson J.D., Bhattacharya R., Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci USA 2013, 110:6700-6705.
119. Cooke V.G., LeBleu V.S., Keskin D., et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21:66-81.
120. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
121. Conde J., Larguinho M., Cordeiro A., et al. Gold-nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis. Nanotoxicology 2014, 8:521-532.
122. Bhattacharya R., Mukherjee P., Xiong Z., Atala A., Soker S., Mukhopadhyay D. Gold nanoparticles inhibit VEGF165-induced proliferation of HUVEC cells. Nano Lett 2004, 4:2479-2481.
123. Mukherjee P., Bhattacharya R., Wang P., et al. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005, 11:3530-3534.
124. Arvizo R.R., Rana S., Miranda O.R., Bhattacharya R., Rotello V.M., Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomed Nanotechnol Biol Med 2011, 7:580-587.
125. Elghanian R., Storhoff J.J., Mucic R.C., Letsinger R.L., Mirkin C.A. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 1997, 277:1078-1081.
126. Gromer S., Arscott L.D., Williams C.H., Schirmer R.H., Becker K. Human placenta thioredoxin reductase isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 1998, 273:20096-20101.
127. Barnard P.J., Berners-Price S.J. Targeting the mitochondrial cell death pathway with gold compounds. Coord Chem Rev 2007, 251:1889-1902.
128. McKeage M.J., Berners-Price S.J., Galettis P., et al. Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemother Pharmacol 2000, 46:343-350.
129. Mukherjee P., Bhattacharya R., Bone N., et al. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology 2007, 5:1-13.
130. Munaron L., Fiorio Pla A. Calcium influx induced by activation of tyrosine kinase receptors in cultured bovine aortic endothelial cells. J Cell Physiol 2000, 185:454-463.
131. Munaron L., Distasi C., Carabelli V., Baccino F., Bonelli G., Lovisolo D. Sustained calcium influx activated by basic fibroblast growth factor in Balb-c 3T3 fibroblasts. J Physiol 1995, 484:557-566.
132. Estacion M., Mordan L. Competence induction by PDGF requires sustained calcium influx by a mechanism distinct from storage-dependent calcium influx. Cell Calcium 1993, 14:439-454.
133. Magni M., Meldolesi J., Pandiella A. Ionic events induced by epidermal growth factor, Evidence that hyperpolarization and stimulated cation influx play a role in the stimulation of cell growth. J Biol Chem 1991, 266:6329-6335.
134. Parenti A., Morbidelli L., Cui X-L., et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 1998, 273:4220-4226.
135. Mac Wu H., Yuan Y., Zawieja D.C., Tinsley J., Granger H.J. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am J Physiol 1999, 276:535-542.
136. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001, 22:201-207.
137. Nie D., Tang K., Diglio C., Honn K.V. Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 2000, 95:2304-2311.
138. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000, 1:11-21.
139. Kahl C.R., Means A.R. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr Rev 2003, 24:719-736.
140. Santella L. The role of calcium in the cell cycle: facts and hypotheses. Biochem Biophys Res Commun 1998, 244:317-324.
141. Munaron L. Calcium signalling and control of cell proliferation by tyrosine kinase receptors (Review). Int J Mol Med 2002, 10:671-676.
142. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
143. Soff G.A. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000, 19:97-107.
144. Jiang L., Jha V., Dhanabal M., Sukhatme V.P., Alper S.L. Intracellular Ca2+ signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. Am J Physiol Cell Physiol 2001, 280:C1140-C1150.
145. Fang C., Illingworth C.D., Qian L., Wormstone I.M. Serum deprivation can suppress receptor-mediated calcium signaling in pterygial-derived fibroblasts. Invest Ophthalmol Visual Sci 2013, 54:4563-4570.
146. Coroneo M., Di Girolamo N., Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 1999, 10:282-288.
147. Liang K., Jiang Z., Zhao B., Shen J., Huang D., Tao L. The expression of vascular endothelial growth factor in mast cells promotes the neovascularisation of human pterygia. Br J Ophthalmol 2012, 96:1246-1251.